Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin

Virology Journal

Volumn 8, Issue , 2011, Pages

  Flusin, Olivier ^a   Vigne, Solenne ^a,c   Peyrefitte, Christophe N ^a   Bouloy, Michèle ^b   Crance, Jean Marc ^a   Iseni, Frédéric ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NUCLEOPROTEIN; RIBAVIRIN; SMALL INTERFERING RNA; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT;

ANTIVIRAL ACTIVITY; ARTICLE; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG EFFICACY; GENE TARGETING; HAZARA NAIROVIRUS; HUMAN; HUMAN CELL; NAIRO VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; CELL LINE; CERCOPITHECUS; DRUG EFFECT; DRUG POTENTIATION; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY;

BUNYAVIRIDAE; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DHORI VIRUS; HAZARA VIRUS; NAIROVIRUS; ORTHOBUNYAVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; NAIROVIRUS; RIBAVIRIN; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 79956188192     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-249     Document Type: Article

References (71)

1. Crimean-Congo hemorrhagic fever. CA Whitehouse, Antiviral Res 2004 64 145 160 15550268 (Pubitemid 39506835)
2. Bunyaviridae: The Viruses and their Replication. CS Schmaljohn ST Nichol, Fields Virology Philadelphia: Lippincott Williams & Wilkins, Knipe DM HPM, Griffin DE, Fifth 2007 2 1741 1789
3. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. H Hoogstraal, J Med Entomol 1979 15 307 417 113533
4. Crimean-Congo haemorrhagic fever. O Ergonul, Lancet Infect Dis 2006 6 203 214 10.1016/S1473-3099(06)70435-2 16554245
5. Crimean-Congo Hemorrhagic fever: basics for general practitioners. O Flusin F Iseni R Rodrigues G Paranhos-Baccal JM Crance P Marianneau M Bouloy CN Peyrefitte, Med Trop 2010 70 429 438
6. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. HC Maltezou L Andonova R Andraghetti M Bouloy O Ergonul F Jongejan N Kalvatchev S Nichol M Niedrig A Platonov G Thomson K Leitmeyer H Zeller, Euro Surveill 2010 15 19504 20403306
7. Crimean-Congo hemorrhagic fever: risk for emergence of new endemic foci in Europe? HC Maltezou A Papa, Travel Med Infect Dis 2010 8 139 143 10.1016/j.tmaid.2010.04.008 20541133
8. Tick-borne viruses of West Pakistan. IV. Viruses similar to or identical with, Crimean hemorrhagic fever (Congo-Semunya), Wad Medani and Pak Argas 461 isolated from ticks of the Changa Manga Forest, Lahore District, and of Hunza, Gilgit Agency, W. Pakistan. F Begum CL Wisseman Jr J Casals, Am J Epidemiol 1970 92 197 202 5458948
9. Results of a preliminary seroepidemiological survey for Crimean-Congo hemorrhagic fever virus in Egypt. MA Darwish IZ Imam FM Omar H Hoogstraal, Acta Virol 1978 22 77 25013
10. The high genetic variation of viruses of the genus Nairovirus reflects the diversity of their predominant tick hosts. JE Honig JC Osborne ST Nichol, Virology 2004 318 10 16 10.1016/j.virol.2003.09.021 14972529 (Pubitemid 38234255)
11. A sero-epidemiological survey for Bunyaviridae and certain other arboviruses in Pakistan. MA Darwish H Hoogstraal TJ Roberts R Ghazi T Amer, Trans R Soc Trop Med Hyg 1983 77 446 450 10.1016/0035-9203(83)90108-6 6415873
12. Experimental Hazara Virus infection in mice. SE Smirnova NM Shestopalova VN Reingold GL Zubri MP Chumakov, Acta Virol 1977 21 128 132 17280 (Pubitemid 8078200)
13. Structural polypeptides of Hazara virus. RS Foulke RR Rosato GR French, J Gen Virol 1981 53 169 172 10.1099/0022-1317-53-1-169 7276913 (Pubitemid 12252822)
14. Bunyaviridae genome structure and gene expression. RM Elliott CS Schmaljohn MS Collett, Curr Top Microbiol Immunol 1991 169 91 141 1935231
15. Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins. S Haferkamp L Fernando TF Schwarz H Feldmann R Flick, Virol J 2005 2 42 10.1186/1743-422X-2-42 15850490
16. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. DM Watts MA Ussery D Nash CJ Peters, Am J Trop Med Hyg 1989 41 581 585 2510529 (Pubitemid 20000631)
17. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. GH Tignor CA Hanham, Antiviral Res 1993 22 309 325 10.1016/0166-3542(93)90040-P 8279818 (Pubitemid 23340819)
18. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. DA Bente JB Alimonti WJ Shieh G Camus U Stroher S Zaki SM Jones, J Virol 2010 84 11089 11100 10.1128/JVI.01383-10 20739514
19. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. H Bodur A Erbay E Akinci P Onguru N Bayazit SS Eren A Kubar, Int J Infect Dis 2010
20. DEBATE (see Elaldi N et al, Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244): Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. O Ergonul, J Infect 2009 59 284 286 author reply 286-289. 10.1016/j.jinf.2009.08.006 19699762
21. Ribavirin in crimean-congo hemorrhagic fever: primum non nocere. O Ergonul A Celikbas B Dokuzoguz S Eren N Baykam H Esener, Clin Infect Dis 2009 49 1621 1622 10.1086/644778 19857172
22. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. A Fire S Xu MK Montgomery SA Kostas SE Driver CC Mello, Nature 1998 391 806 811 10.1038/35888 9486653 (Pubitemid 28099681)
23. RNA interference is mediated by 21- and 22-nucleotide RNAs. SM Elbashir W Lendeckel T Tuschl, Genes Dev 2001 15 188 200 10.1101/gad.862301 11157775 (Pubitemid 32107664)
24. Dicing and slicing: the core machinery of the RNA interference pathway. SM Hammond, FEBS Lett 2005 579 5822 5829 10.1016/j.febslet.2005.08.079 16214139 (Pubitemid 41484128)
25. Modulation of HIV-1 replication by RNA interference. JM Jacque K Triques M Stevenson, Nature 2002 418 435 438 10.1038/nature00896 12087358 (Pubitemid 34826845)
26. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. P Kumar HS Ban SS Kim H Wu T Pearson DL Greiner A Laouar J Yao V Haridas K Habiro YG Yang JH Jeong KY Lee YH Kim SW Kim M Peipp GH Fey N Manjunath LD Shultz SK Lee P Shankar, Cell 2008 134 577 586 10.1016/j.cell.2008.06.034 18691745
27. Inhibition of influenza virus production in virus-infected mice by RNA interference. Q Ge L Filip A Bai T Nguyen HN Eisen J Chen, Proc Natl Acad Sci USA 2004 101 8676 8681 10.1073/pnas.0402486101 15173599 (Pubitemid 38745830)
28. Protection against lethal influenza virus challenge by RNA interference in vivo. SM Tompkins CY Lo TM Tumpey SL Epstein, Proc Natl Acad Sci USA 2004 101 8682 8686 10.1073/pnas.0402630101 15173583 (Pubitemid 38745831)
29. Inhibition of respiratory viruses by nasally administered siRNA. V Bitko A Musiyenko O Shulyayeva S Barik, Nat Med 2005 11 50 55 10.1038/nm1164 15619632 (Pubitemid 40215837)
30. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). J DeVincenzo JE Cehelsky R Alvarez S Elbashir J Harborth I Toudjarska L Nechev V Murugaiah A Van Vliet AK Vaishnaw R Meyers, Antiviral Res 2008 77 225 231 10.1016/j.antiviral.2007.11.009 18242722
31. Small interfering RNA inhibits hepatitis B virus replication in mice. H Giladi M Ketzinel-Gilad L Rivkin Y Felig O Nussbaum E Galun, Mol Ther 2003 8 769 776 10.1016/S1525-0016(03)00244-2 14599810 (Pubitemid 37527452)
32. Short interfering RNA-directed inhibition of hepatitis B virus replication. K Hamasaki K Nakao K Matsumoto T Ichikawa H Ishikawa K Eguchi, FEBS Lett 2003 543 51 54 10.1016/S0014-5793(03)00400-9 12753904 (Pubitemid 36577226)
33. Inhibition of hepatitis B virus in mice by RNA interference. AP McCaffrey H Nakai K Pandey Z Huang FH Salazar H Xu SF Wieland PL Marion MA Kay, Nat Biotechnol 2003 21 639 644 10.1038/nbt824 12740585 (Pubitemid 36638090)
34. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. RS Ying C Zhu XG Fan N Li XF Tian HB Liu BX Zhang, Antiviral Res 2007 73 24 30 10.1016/j.antiviral.2006.05.022 16844238 (Pubitemid 46080475)
35. Interference of hepatitis C virus RNA replication by short interfering RNAs. SB Kapadia A Brideau-Andersen FV Chisari, Proc Natl Acad Sci USA 2003 100 2014 2018 10.1073/pnas.252783999 12566571 (Pubitemid 36254565)
36. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. MY Seo S Abrignani M Houghton JH Han, J Virol 2003 77 810 812 10.1128/JVI.77.1.810-812.2003 12477890 (Pubitemid 36005024)
37. Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. S Khaliq S Jahan B Ijaz W Ahmad S Asad A Pervaiz B Samreen M Khan S Hassan, Virol J 2010 7 318 10.1186/1743-422X-7-318 21073745
38. Inhibition of Marburg virus protein expression and viral release by RNA interference. T Fowler S Bamberg P Moller HD Klenk TF Meyer S Becker T Rudel, J Gen Virol 2005 86 1181 1188 10.1099/vir.0.80622-0 15784912 (Pubitemid 40485676)
39. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. TW Geisbert LE Hensley E Kagan EZ Yu JB Geisbert K Daddario-DiCaprio EA Fritz PB Jahrling K McClintock JR Phelps AC Lee A Judge LB Jeffs I MacLachlan, J Infect Dis 2006 193 1650 1657 10.1086/504267 16703508 (Pubitemid 43839469)
40. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. TW Geisbert AC Lee M Robbins JB Geisbert AN Honko V Sood JC Johnson S de Jong I Tavakoli A Judge LE Hensley I Maclachlan, Lancet 2010 375 1896 1905 10.1016/S0140-6736(10) 60357-1 20511019
41. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. AD Judge V Sood JR Shaw D Fang K McClintock I MacLachlan, Nat Biotechnol 2005 23 457 462 10.1038/nbt1081 15778705 (Pubitemid 41724921)
42. Activation of the interferon system by short-interfering RNAs. CA Sledz M Holko MJ de Veer RH Silverman BR Williams, Nat Cell Biol 2003 5 834 839 10.1038/ncb1038 12942087 (Pubitemid 37087172)
43. Treatment of Crimean-Congo hemorrhagic fever. O Ergonul, Antiviral Res 2008 78 125 131 10.1016/j.antiviral.2007.11.002 18096251
44. Nairovirus RNA sequences expressed by a Semliki Forest virus replicon induce RNA interference in tick cells. S Garcia A Billecocq JM Crance U Munderloh D Garin M Bouloy, J Virol 2005 79 8942 8947 10.1128/JVI.79.14.8942- 8947.2005 15994788 (Pubitemid 40934805)
45. Pathogen-specific resistance to Rift Valley fever virus infection is induced in mosquito cells by expression of the recombinant nucleoprotein but not NSs non-structural protein sequences. A Billecocq M Vazeille-Falcoz F Rodhain M Bouloy, J Gen Virol 2000 81 2161 2166 10950972
46. Molecularly engineered resistance to California serogroup virus replication in mosquito cells and mosquitoes. AM Powers KI Kamrud KE Olson S Higgs JO Carlson BJ Beaty, Proc Natl Acad Sci USA 1996 93 4187 4191 10.1073/pnas.93.9.4187 8633038 (Pubitemid 26144260)
47. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. SS Soldan ML Plassmeyer MK Matukonis F Gonzalez-Scarano, J Virol 2005 79 234 244 10.1128/JVI.79.1.234-244.2005 15596819 (Pubitemid 39648379)
48. Highly effective inhibition of Akabane virus replication by siRNA genes. A Levin L Kutznetova R Kahana M Rubinstein-Guini Y Stram, Virus Res 2006 120 121 127 10.1016/j.virusres.2006.02.009 16616390 (Pubitemid 43947307)
49. Evolution of Crimean-Congo Hemorrhagic Fever virus. V Anagnostou A Papa, Infect Genet Evol 2009 9 948 954 10.1016/j.meegid.2009.06.018 19560561
50. Crimean-Congo hemorrhagic fever virus genomics and global diversity. VM Deyde ML Khristova PE Rollin TG Ksiazek ST Nichol, J Virol 2006 80 8834 8842 10.1128/JVI.00752-06 16912331 (Pubitemid 44384893)
51. Antigen-capture enzyme-linked immunosorbent assay for the diagnosis of crimean-congo hemorrhagic fever using a novel monoclonal antibody. M Saijo Q Tang B Shimayi L Han Y Zhang M Asiguma D Tianshu A Maeda I Kurane S Morikawa, J Med Virol 2005 77 83 88 10.1002/jmv.20417 16032715 (Pubitemid 41076481)
52. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. S Vigne R Germi S Duraffour S Larrat G Andrei R Snoeck D Garin JM Crance, Antivir Ther 2008 13 357 368 18572748 (Pubitemid 352016728)
53. Inhibition of monkeypox virus replication by RNA interference. A Alkhalil S Strand E Mucker JW Huggins PB Jahrling SM Ibrahim, Virol J 2009 6 188 10.1186/1743-422X-6-188 19889227
54. Inhibition of virus replication by RNA interference. PC Haasnoot D Cupac B Berkhout, J Biomed Sci 2003 10 607 616 14576463
55. Targeted delivery of siRNA. S Oliveira G Storm RM Schiffelers, J Biomed Biotechnol 2006 2006 63675 17057365
56. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. D Castanotto K Sakurai R Lingeman H Li L Shively L Aagaard H Soifer A Gatignol A Riggs JJ Rossi, Nucleic Acids Res 2007 35 5154 5164 10.1093/nar/gkm543 17660190 (Pubitemid 47394199)
57. Competition for RISC binding predicts in vitro potency of siRNA. E Koller S Propp H Murray W Lima B Bhat TP Prakash CR Allerson EE Swayze EG Marcusson NM Dean, Nucleic Acids Res 2006 34 4467 4476 10.1093/nar/gkl589 16945958 (Pubitemid 44567046)
58. Inhibition of Epstein-Barr virus replication by small interfering RNA targeting the Epstein-Barr virus protease gene. S Larrat P Morand A Bas S Vigne JM Crance V Boyer S Nicod L Grossi M Buisson WP Burmeister JM Seigneurin R Germi, Antivir Ther 2009 14 655 662 19704168
59. Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. S Vigne S Duraffour G Andrei R Snoeck D Garin JM Crance, Antimicrob Agents Chemother 2009 53 2579 2588 10.1128/AAC.01626-08 19307376
60. Is RNA interference feasible for the control of foot-and-mouth disease outbreaks? J Bayry DF Tough, Trends Immunol 2005 26 238 239 discussion 239-241. 10.1016/j.it.2005.03.003 15866234
61. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. E Song SK Lee DM Dykxhoorn C Novina D Zhang K Crawford J Cerny PA Sharp J Lieberman N Manjunath P Shankar, J Virol 2003 77 7174 7181 10.1128/JVI.77.13.7174-7181.2003 12805416 (Pubitemid 36734486)
62. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. DL DiGiusto A Krishnan L Li H Li S Li A Rao S Mi P Yam S Stinson M Kalos J Alvarnas SF Lacey JK Yee M Li L Couture D Hsu SJ Forman JJ Rossi JA Zaia, Sci Transl Med 2010 2 36ra43 20555022
63. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. J DeVincenzo R Lambkin-Williams T Wilkinson J Cehelsky S Nochur E Walsh R Meyers J Gollob A Vaishnaw, Proc Natl Acad Sci USA 2010 107 8800 8805 10.1073/pnas.0912186107 20421463
64. Therapeutic application of RNA interference for hepatitis C virus. T Watanabe T Umehara M Kohara, Adv Drug Deliv Rev 2007 59 1263 1276 10.1016/j.addr.2007.03.022 17822803 (Pubitemid 350030325)
65. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. N Sakamoto Y Tanabe T Yokota K Satoh Y Sekine-Osajima M Nakagawa Y Itsui M Tasaka Y Sakurai C Cheng-Hsin M Yano S Ohkoshi Y Aoyagi S Maekawa N Enomoto M Kohara M Watanabe, J Gastroenterol Hepatol 2008 23 1437 1447 10.1111/j.1440-1746.2007.05076.x 17683479
66. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. DV Morrissey K Blanchard L Shaw K Jensen JA Lockridge B Dickinson JA McSwiggen C Vargeese K Bowman CS Shaffer BA Polisky S Zinnen, Hepatology 2005 41 1349 1356 10.1002/hep.20702 15880588 (Pubitemid 40770288)
67. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. DV Morrissey JA Lockridge L Shaw K Blanchard K Jensen W Breen K Hartsough L Machemer S Radka V Jadhav N Vaish S Zinnen C Vargeese K Bowman CS Shaffer LB Jeffs A Judge I MacLachlan B Polisky, Nat Biotechnol 2005 23 1002 1007 10.1038/nbt1122 16041363 (Pubitemid 41114035)
68. Effective inhibition of hepatitis E virus replication in A549 cells and piglets by RNA interference (RNAi) targeting RNA-dependent RNA polymerase. F Huang X Hua S Yang C Yuan W Zhang, Antiviral Res 2009 83 274 281 10.1016/j.antiviral.2009.06.008 19576249
69. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. DC Quenelle MN Prichard KA Keith DE Hruby R Jordan GR Painter A Robertson ER Kern, Antimicrob Agents Chemother 2007 51 4118 4124 10.1128/AAC.00762-07 17724153 (Pubitemid 350057813)
70. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. H Nakata SM Steinberg Y Koh K Maeda Y Takaoka H Tamamura N Fujii H Mitsuya, Antimicrob Agents Chemother 2008 52 2111 2119 10.1128/AAC.01299-07 18378711 (Pubitemid 351758548)
71. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. NC Schopman O ter Brake B Berkhout, Retrovirology 2010 7 52 10.1186/1742-4690-7-52 20529316